Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions. The Company’s current area of research focus is Overactive Bladder (OAB). Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.